Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates

Igor S. Lukashevich, Ricardo Carrion, Maria S. Salvato, Keith Mansfield, Kathleen Brasky, Juan Zapata, Cristiana Cairo, Marco Goicochea, Gia E. Hoosien, Anysha Ticer, Joseph Bryant, Harry Davis, Rasha Hammamieh, Maria Mayda, Marti Jett, Jean Patterson

    Research output: Contribution to journalArticlepeer-review

    81 Scopus citations

    Abstract

    A single injection of ML29 reassortant vaccine for Lassa fever induces low, transient viremia, and low or moderate levels of ML29 replication in tissues of common marmosets depending on the dose of the vaccination. The vaccination elicits specific immune responses and completely protects marmosets against fatal disease by induction of sterilizing cell-mediated immunity. DNA array analysis of human peripheral blood mononuclear cells from healthy donors exposed to ML29 revealed that gene expression patterns in ML29-exposed PBMC and control, media-exposed PBMC, clustered together confirming safety profile of the ML29 in non-human primates. The ML29 reassortant is a promising vaccine candidate for Lassa fever.

    Original languageEnglish (US)
    Pages (from-to)5246-5254
    Number of pages9
    JournalVaccine
    Volume26
    Issue number41
    DOIs
    StatePublished - Sep 26 2008

    Keywords

    • Arenaviruses
    • Lassa fever
    • Protection
    • Vaccine

    ASJC Scopus subject areas

    • Molecular Medicine
    • Immunology and Microbiology(all)
    • veterinary(all)
    • Public Health, Environmental and Occupational Health
    • Infectious Diseases

    Fingerprint Dive into the research topics of 'Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates'. Together they form a unique fingerprint.

    Cite this